NantHealth (NASDAQ:NH) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Tuesday, January 9th.
NH has been the subject of several other reports. Zacks Investment Research downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Jefferies Group reiterated a “buy” rating and issued a $5.00 target price on shares of NantHealth in a research note on Thursday, September 28th. Finally, Canaccord Genuity dropped their target price on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $8.05.
NantHealth (NASDAQ:NH) traded down $0.04 during mid-day trading on Tuesday, reaching $3.09. 18,911 shares of the company traded hands, compared to its average volume of 162,563. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93. NantHealth has a 1-year low of $2.60 and a 1-year high of $8.16.
NantHealth (NASDAQ:NH) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. The firm had revenue of $21.76 million for the quarter, compared to analyst estimates of $29.42 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. equities analysts anticipate that NantHealth will post -1.35 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the company. Highbridge Capital Management LLC increased its holdings in shares of NantHealth by 6.5% in the 3rd quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock worth $1,030,000 after buying an additional 15,264 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of NantHealth by 132.4% during the 2nd quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock valued at $134,000 after purchasing an additional 18,000 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of NantHealth by 40.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 63,149 shares of the company’s stock valued at $260,000 after purchasing an additional 18,300 shares during the last quarter. Alliancebernstein L.P. bought a new position in shares of NantHealth during the 2nd quarter valued at $102,000. Finally, National Planning Corp grew its holdings in shares of NantHealth by 21.1% during the 3rd quarter. National Planning Corp now owns 138,700 shares of the company’s stock valued at $656,000 after purchasing an additional 24,200 shares during the last quarter. 7.12% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/05/bidaskclub-upgrades-nanthealth-nh-to-sell.html.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.